AIM: To evaluate the expression of eukaryotic initiation factors 3(eIF3) subunit 170 (eIF3 P170) in lung cancer tissues and its association with chemotherapy response of lung cancer. METHODS: 31 paraffin imbedded slic...AIM: To evaluate the expression of eukaryotic initiation factors 3(eIF3) subunit 170 (eIF3 P170) in lung cancer tissues and its association with chemotherapy response of lung cancer. METHODS: 31 paraffin imbedded slices of lung cancer tissue from fiberscope diagnosis, 20 samples of benign lung tissues from inflammatory pseudotumor and bronchiectasis, and 10 samples of normal lung tissues from surgical operation were collected. The protein expression of eIF3 p170 in lung-cancer tissues, benign lesion tissues, and normal lung tissues were determined by immunohistochemical staining. RESULTS: The positive ratio of eIF3 p170 expression in lung cancer tissues is higher than those in normal and benign tissues, the lung cancer patients with a higher expression level of eIF3 p170 seems to be more sensitive to chemotherapy. Here, we also found that down-regulation of expression of eIF3 p170 could inhibit the growth of human lung adeno-carcinoma cell A549 cells and decrease the sensitivity of A549 to cisplatin. CONCLUSION: Our data suggest that eIF3 p170 may be involved in the pathogenesis of lung cancer and it appears to be associated with chemotherapy response of lung cancer.展开更多
基金This project was supported by the National Natural Science Foundation of China grant(No 30572230) the Supported Program for New Century Excellent Talents in University (NCET-04-0749) sponsored by Ministry of Education of China .
文摘AIM: To evaluate the expression of eukaryotic initiation factors 3(eIF3) subunit 170 (eIF3 P170) in lung cancer tissues and its association with chemotherapy response of lung cancer. METHODS: 31 paraffin imbedded slices of lung cancer tissue from fiberscope diagnosis, 20 samples of benign lung tissues from inflammatory pseudotumor and bronchiectasis, and 10 samples of normal lung tissues from surgical operation were collected. The protein expression of eIF3 p170 in lung-cancer tissues, benign lesion tissues, and normal lung tissues were determined by immunohistochemical staining. RESULTS: The positive ratio of eIF3 p170 expression in lung cancer tissues is higher than those in normal and benign tissues, the lung cancer patients with a higher expression level of eIF3 p170 seems to be more sensitive to chemotherapy. Here, we also found that down-regulation of expression of eIF3 p170 could inhibit the growth of human lung adeno-carcinoma cell A549 cells and decrease the sensitivity of A549 to cisplatin. CONCLUSION: Our data suggest that eIF3 p170 may be involved in the pathogenesis of lung cancer and it appears to be associated with chemotherapy response of lung cancer.
